News
The conversation centred on the company’s latest developments and strategic direction in cancer therapies, with a particular ...
What trends did delegates notice, in terms of new modalities, technologies, and approaches? Precision, personalisation, and ...
Summit Pharma has revealed that a second pivotal trial of its Akeso-partnered PD-1xVEGF bispecific ivonescimab has failed to ...
The deal with Evopoint boosts Astellas' claudin pipeline as other CLDN18.2 candidates come through the industry pipeline from ...
Roche has revealed new results from a phase 2 trial of its oral BTK inhibitor fenebrutinib in relapsing multiple sclerosis (MS) that suggest it can prevent progression of the disease for nearly two ...
Philippe Masset has been appointed to the Board of Directors at Vect-Horus, a French biotech developing vectors for targeting ...
Op den Kelder grew up in the Netherlands and received his Bachelor’s degree in International Management from Fontys ...
Stealth refrained from criticising the FDA's decision on its application, which comes after the agency missed its own ...
Angelini is paying $50 million upfront for ex-North American rights to radiprodil, with another $520 million in the offing in ...
This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...
The pharmaceutical industry is quickly evolving; to stay relevant and competitive, companies need to stay on top of the most recent trends and technologies. One important piece of the puzzle that ...
New research reveals some significant imbalances between healthcare professionals' (HCP) demand and industry's provision of medical information, based on content types, channels and format.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results